V-Wave Ltd. news

V-Wave Ltd, manufacturer of the V-Wave Ventura investigational interatrial shunt device to help patients with advanced heart failure (HF), announced 12-month echocardiographic results from the open label Roll-in arm of the RELIEVE-HF pivotal clinical trial, comprising 97 NYHA Class III or ambulatory Class IV HF patients who were already on maximally tolerated guideline directed medical therapy. The patients were enrolled in 57 hospitals from 8 countries. The findings were presented at the Eur

V-Wave Ltd., a cardiovascular device company developing proprietary, minimally invasive interatrial shunt devices for treating patients with severe symptomatic heart failure (HF) and pulmonary arterial hypertension (PAH), announced the appointment of Bill Hughes as its Chief Financial Officer (CFO) today.

“We are thrilled to add someone with Bill’s talent and experience to the V-Wave management team,” said Dr. Neal Eigler, V-Wave’s CEO. “Bill will be an e

Location: Caesarea, Israel and Agoura California

V-Wave Ltd., a cardiovascular device company developing proprietary, minimally invasive interatrial shunt devicesfor treating patients with severe symptomatic heart failure (HF) and pulmonary arterial hypertension (PAH), announced today that it has successfully closed all remaining tranches of the Series C extension totaling $98M. The financing assures capital to complete the clinical trial for the Ventura® Interatr

V-Wave Ltd., a cardiovascular device company developing proprietary, minimally invasive interatrial shunt devices for treating patients with severe symptomatic heart failure (HF) and pulmonary arterial hypertension (PAH), announced today that it has closed a Series C extension of up to $98M. The financing assures capital to complete clinical trials for the Ventura® Interatrial Shunt for the treatment of advanced heart failure and to obtain FDA clearance subject to final data and agency re

V-Wave Ltd., an early stage medtech company developing an implantable interatrial shunt device for treating advanced heart failure (HF) and pulmonary arterial hypertension (PAH), announced today that renowned heart failure cardiologist, William T. Abraham, MD, is joining V-Wave as Chief Medical Officer. Dr. Abraham makes this move to V-Wave after more than 16 years as Director of the Division of Cardiovascular Medicine at the Ohio State University.

Dr. Abraham has vast clinical trial